Drug delivery systems are under intense investigation all around the world, especially in
oncology research. Indeed, in some cases, like bone metastasis, nanodrugs may represent the last and
best choice for both treatment and imaging of early cancer foci. Nuclear medicine has been using MDP
labelled with 99mTc as radiopharmaceuticals for many years; however, their use as nanoradiopharmaceuticals
is very innovative and creates a new way to establish radiopharmacy in this new
scenario offered by nanotechnology. In this study we developed and tested nano-MDP-labelled with
99mTc in rats induced with bone cancer metastasis and the results showed that it may work in patients. However, some
further experiments are required in order to initiate protocols in humans.